These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35798648)

  • 1. Re: Julia Dagnæs-Hansen, Gitte Hjartbro Kristensen, Hein V. Stroomberg, Søren Schwartz Sørensen, Martin Andreas Røder. Surgical Approaches and Outcomes in Living Donor Nephrectomy: A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.03.021.
    Pecoraro A; Li Marzi V; Serni S; Campi R
    Eur Urol Focus; 2023 Jan; 9(1):216-217. PubMed ID: 35798648
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Alessio Pecoraro, Vincenzo Li Marzi, Sergio Serni, and Riccardo Campi's Letter to the Editor re: Julia Dagnæs-Hansen, Gitte Hjartbro Kristensen, Hein V. Stroomberg, Søren Schwartz Sørensen, Martin Andreas Røder. Surgical Approaches and Outcomes in Living Donor Nephrectomy: A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.03.021.
    Dagnæs-Hansen J; Hjartbro Kristensen G; Stroomberg HV; Schwartz Sørensen S; Røder MA
    Eur Urol Focus; 2023 Jan; 9(1):218. PubMed ID: 35803853
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Hein V. Stroomberg, Signe Benzon Larsen, Torben Kjær Nielsen, J. Thomas Helgstrand, Klaus Brasso, Andreas Røder. Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.005.
    Gallo G; Lombardo R; De Nunzio C
    Eur Urol Oncol; 2024 Jun; 7(3):646-647. PubMed ID: 38290922
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002.
    Montorsi F; Larcher A; Capitanio U
    Eur Urol Focus; 2021 Mar; 7(2):406. PubMed ID: 31564640
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Andrea Mari, Riccardo Tellini, Francesco Porpiglia, et al. Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score ≥10) Renal Tumors: A Prospective Multicenter Observational Study (the RECORD2 Project). Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.07.004.
    Grivas N; Goonewardene S; Everaerts W; Kalampokis N;
    Eur Urol Focus; 2021 Sep; 7(5):1210-1211. PubMed ID: 33358885
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Jordan M. Rich, Kennedy E. Okhawere, Charles Nguyen, et al. Transperitoneal Versus Retroperitoneal Single-port Robotic-assisted Partial Nephrectomy: An Analysis from the Single Port Advanced Research Consortium. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.004.
    Wan S; Li KP; Yang L
    Eur Urol Focus; 2024 May; 10(3):493-494. PubMed ID: 37722953
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Nikolaos Grivas, Sanchia Goonewardene, Wouter Everaerts, Nikolaos Kalampokis's Letter to the Editor re: Andrea Mari, Riccardo Tellini, Francesco Porpiglia, et al. Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score ≥10) Renal Tumors: A Prospective Multicenter Observational Study (the RECORD2, Project). Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.07.004.
    Mari A; Tellini R; Ficarra V; Carini M; Minervini A;
    Eur Urol Focus; 2021 Sep; 7(5):1212-1213. PubMed ID: 33384273
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
    Singla N; Margulis V
    Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
    Uleri A; Baboudjian M; Diamand R; Ploussard G
    Eur Urol; 2024 Sep; 86(3):e66. PubMed ID: 38796382
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Shun Wan, Kun-peng Li, and Li Yang's Letter to the Editor re: Jordan M. Rich, Kennedy E. Okhawere, Charles Nguyen, et al. Transperitoneal Versus Retroperitoneal Single-port Robotic-assisted Partial Nephrectomy: An Analysis from the Single Port Advanced Research Consortium. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.004.
    Rich JM; Okhawere KE; Razdan S; Badani KK
    Eur Urol Focus; 2024 May; 10(3):495-496. PubMed ID: 37739915
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Patel HD; Allaf ME
    Eur Urol; 2013 Nov; 64(5):e105-6. PubMed ID: 23910939
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print].
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2021 Mar; 7(2):404-405. PubMed ID: 31679868
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Longbin Xiong, Jane K. Nguyen, Yulu Peng, et al. What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy? Eur Urol. 2022;81:492-500. https://doi.org/10.1016/j.eururo.2021.12.036.
    Ren S; Zhong S; Fan S; Li X; Zhou F; Wang D
    Eur Urol; 2022 Aug; 82(2):e49. PubMed ID: 35570147
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
    Wei Y; Zhang R; Lin L
    Eur Urol; 2022 Sep; 82(3):e88. PubMed ID: 35750581
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Sun M; Karakiewicz PI; Trinh QD
    Eur Urol; 2013 Nov; 64(5):e107-8. PubMed ID: 23910940
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Rui Farinha, Giuseppe Rosiello, Artur De Oliveira Paludo, et al. Selective Suturing or Sutureless Technique in Robot-assisted Partial Nephrectomy: Results from a Propensity-score Matched Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.019.
    Grivas N; van der Poel HG
    Eur Urol Focus; 2022 May; 8(3):887. PubMed ID: 34016555
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8.
    Sharma P; Sawar A; Spiess P
    Eur Urol; 2015 Oct; 68(4):e79-80. PubMed ID: 26007640
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606-17.
    Kim JH; Chung BI
    Eur Urol; 2017 Nov; 72(5):e127-e128. PubMed ID: 28545840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.